Keywords: gsk, avandia, cleared, cv, death, risk, trial

GSK's Avandia cleared of CV death risk; trial questions aggressive HbA1c cuts

Article | 18 February 2008

Print This

A report from the US National Heart, Lung and Blood Institute has found that GlaxoSmithKline's diabetes drug Avandia (rosiglitazone) was ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in